BlackRock
APGE icon

BlackRock’s Apogee Therapeutics APGE Stock Holding History

BlackRock’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$731M Buy
5,507,032
+1,421,381
+35% +$128M 0.01% 936
2026
Q1 		$344M Buy
4,085,651
+301,657
+8% +$21.9M 0.01% 1348
2025
Q4 		$286M Buy
3,783,994
+1,097,968
+41% +$69.2M ﹤0.01% 1463
2025
Q3 		$107M Buy
2,686,026
+123,487
+5% +$4.72M ﹤0.01% 2064
2025
Q2 		$111M Sell
2,562,539
-348,290
-12% -$13.2M ﹤0.01% 1971
2025
Q1 		$109M Sell
2,910,829
-134,129
-4% -$5.19M ﹤0.01% 1929
2024
Q4 		$138M Buy
3,044,958
+69,041
+2% +$3.52M ﹤0.01% 1889
2024
Q3 		$175M Buy
2,975,917
+233,368
+9% +$11.2M ﹤0.01% 1740
2024
Q2 		$108M Sell
2,742,549
-67,276
-2% -$3.27M ﹤0.01% 1974
2024
Q1 		$187M Buy
2,809,825
+1,165,788
+71% +$50.9M ﹤0.01% 1689
2023
Q4 		$45.9M Sell
1,644,037
-17,360
-1% -$348K ﹤0.01% 2526
2023
Q3 		$35.4M Buy
+1,661,397
New +$36.6M ﹤0.01% 2616

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

BlackRock's APGE Position: Q2 2026 in Review

BlackRock increased its Apogee Therapeutics (APGE) stake by 35% in Q2 2026, buying an estimated $128M and bringing the position to 5,507,032 shares worth $731M. The position accounts for 0.01% of the portfolio, ranked #936.

BlackRock first reported a position in APGE in Q3 2023 and has held it in 12 quarters since. 288 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • BlackRock held 5,507,032 shares of Apogee Therapeutics worth $731M as of Q2 2026.
  • BlackRock bought 1,421,381 Apogee Therapeutics shares in Q2 2026, an estimated $128M.
  • Apogee Therapeutics made up 0.01% of BlackRock's portfolio in Q2 2026, its #936 holding.
  • BlackRock first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • 288 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.